MMP-2 His Tag Protein, Mouse,specification,price,image-Bio-Equip in China

Product Detail
Company Profile

Product Specification

Species	Mouse
Synonyms	EC:3.4.24.24，Matrix Metallopeptidase 2 (Gelatinase A， 72kDa Gelatinase， 72kDa Type IV Collagenase)，MMP-2，MMP2，Matrix metalloproteinase-2，72 kDa gelatinase，Matrix Metallopeptidase 2，CLG4A，TBE-1，Matrix Metalloproteinase 2 (Gelatinase A， 72kDa Gelatinase， 72kDa Type IV Collagenase)，Matrix Metalloproteinase 2，Matrix Metalloproteinase-II，72 KDa Type IV Collagenase，Collagenase Type IV-A，Neutrophil Gelatinase，Gelatinase A，EC 3.4.24.24，MMP-II，MONA，CLG4，EC 3.4.24
Accession	P33434
Amino Acid Sequence	Met409-Cys662 with His Tag at C-Terminus
Expression System	HEK293
Molecular Weight	33-43kDa (Reducing)
Purity	＞95% by SDS-PAGE & SEC-HPLC
Endotoxin	<0.1EU/μg
Conjugation	Unconjugated
Tag	His Tag
Physical Appearance	Lyophilized Powder
Storage Buffer	PBS, PH7.4,5% trehalose
Reconstitution	Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
Stability & Storage	· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles.
Reference	1.Thompson EW, et al. (1994) Collagen induced MMP-2 activation in human breast cancer. Breast Cancer Res Treat. 31(2-3): 357-70. 2.Jezierska A, et al. (2009) Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit. 15(2): RA32-40. 3.Fredrich M, et al. (2010) MMP-2 is involved in synaptic remodeling after cochlear lesion. Neuroreport. 21(5): 324-7.

Background

Matrix Metalloproteinase-2 (MMP-2) is an enzyme that degrades extracellular matrix components, playing a pivotal role in cell migration during physiological and pathological processes. Its expression is regulated by EMMPRIN, Her2/neu, growth factors, cytokines, and hormones. Pro-MMP-2 activation requires MT1-MMP and TIMP-2. Low MMP-2 levels are associated with a favorable prognosis in hormone receptor-negative tumors, which are typically high-risk. As a zymogen requiring proteolytic activation, MMP-2 is broadly implicated in cancer invasion and metastasis, including human breast cancer. Blocking MMP-2 secretion and activation during breast carcinoma development may reduce metastasis. The detection of active MMP-2 or the ratio of pro-MMP-2 to active MMP-2 is a highly sensitive indicator of cancer metastasis. Modulating MMP-2 expression and activation via specific inhibitors or activators offers a promising therapeutic strategy for breast cancer treatment.